Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

Abstract Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once-daily, single-tablet regimen for treatment of HIV-1 infection. The efficacy/safety of switching to D/C/F/TAF versus continuing boosted protease inhibitor (bPI) + emtricitabine/tenofov...

Full description

Bibliographic Details
Main Authors: Gregory D. Huhn, Joseph J. Eron, Pierre-Marie Girard, Chloe Orkin, Jean-Michel Molina, Edwin DeJesus, Romana Petrovic, Donghan Luo, Erika Van Landuyt, Erkki Lathouwers, Richard E. Nettles, Kimberley Brown, Eric Y. Wong
Format: Article
Language:English
Published: BMC 2019-08-01
Series:AIDS Research and Therapy
Subjects:
HIV-1
Darunavir
Antiretroviral
Protease inhibitor
Single-tablet regimen
Switch study
Online Access:http://link.springer.com/article/10.1186/s12981-019-0235-1

Internet

http://link.springer.com/article/10.1186/s12981-019-0235-1

Similar Items